| Degrees
|
B.A., University of Texas–Austin, 1992
M.S., Texas A&M University, 1997
Ph.D., Case Western Reserve University, 2005
|
PROJECT DESCRIPTION:
Targeting Breast Cancer Stem Cells
According to the cancer stem cell hypothesis, cells giving rise to drug-resistant breast cancers may be of stem cell origin. Current cancer therapies target highly proliferative cancer cells and molecular alterations that occur in cells that make up the bulk of a solid tumor but not in the quiescent cancer stem cells. Consequently, tumor size is reduced, but aberrant cancer stem cells remain to regenerate tumors and metastatic lesions. To develop novel therapeutics that target cancer stem cells, it is imperative that we identify unique molecular features that define cancer stem cells. Our laboratory is currently utilizing a well-characterized p53 null mouse model, which mimics a subset of human breast cancer, to identify cancer stem cells and pathways that regulate cancer stem cell properties. We hypothesize that manipulation of stem cell self-renewal signaling pathways will alter cancer stem cell survival and tumor potential.
|
PUBLICATIONS:
Landis MD, Seachrist DD, Abdul-Karim FW, Keri RA.
Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.
Oncogene. 2006 Jan 23; [Epub ahead of print]
Landis MD, Seachrist DD, Montanez-Wiscovich ME, Danielpour D, Keri RA.
Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.
Oncogene. 2005 Aug 4;24(33):5173-90.
Milliken EL, Ameduri RK, Landis MD, Behrooz A, Abdul-Karim FW, Keri RA.
Ovarian hyperstimulation by LH leads to mammary gland hyperplasia and cancer predisposition in transgenic mice.
Endocrinology. 2002 Sep;143(9):3671-80.
Landis MD, Carstens GE, McPhail EG, Randel RD, Green KK, Slay L, Smith SB.
Ontogenic development of brown adipose tissue in Angus and Brahman fetal calves.
J Anim Sci. 2002 Mar;80(3):591-601.
|
